Breast Cancer: Current Research
Open Access

Epigenetics; Cancer stem cells; DNA methylation; Histone modification; Non-coding RNA; Tumor initiation; Drug resistance; Tumor relapse; Epigenetic therapies

Introduction

Cancer stem cells (CSCs) are a unique subset of cells within tumors that exhibit the ability to self-renew, differentiate, and drive tumorigenesis. They are also implicated in the development of resistance to conventional therapies and are responsible for tumor relapse and metastasis. The dynamic plasticity of CSCs, their capacity to switch between different phenotypic states, and their interaction with the tumor microenvironment contribute to their survival and malignancy. Recent advances in cancer research have highlighted the crucial role of epigenetic mechanisms in regulating the behavior of CSCs [1-3].

Epigenetics refers to heritable changes in gene expression that do not involve alterations in the DNA sequence. These changes are reversible, making them an attractive target for therapeutic intervention. The main epigenetic mechanisms include DNA methylation, histone modification, and non-coding RNA (ncRNA) regulation. This article aims to provide an overview of these mechanisms as they pertain to CSC biology and explores the potential of targeting epigenetic regulation in CSCs as a novel therapeutic strategy [4-6].

Epigenetic Mechanisms in Cancer Stem Cells

DNA methylation: DNA methylation is a well-studied epigenetic modification where methyl groups are added to the cytosine residues of CpG islands in gene promoters. In CSCs, aberrant DNA methylation patterns can result in the silencing of tumor suppressor genes or the activation of oncogenes, promoting their self-renewal and survival [7].

For example, hypermethylation of the promoter region of the CDH1 gene, which encodes E-cadherin, has been linked to epithelial-mesenchymal transition (EMT) in CSCs, a process crucial for metastasis. On the other hand, hypomethylation can activate oncogenes like c-Myc, further enhancing CSC proliferation. Thus, DNA methylation not only plays a role in maintaining the stemness of CSCs but also contributes to their aggressive behavior [8].

Histone modifications: Histone proteins, which help package DNA into chromatin, are subject to various post-translational modifications, such as acetylation, methylation, phosphorylation, and ubiquitination. These modifications alter chromatin structure and regulate gene accessibility for transcription.

In CSCs, histone modifications are key to regulating gene expression patterns that maintain their stemness. For example, polycomb repressive complex 2 (PRC2) catalyzes the trimethylation of histone H3 lysine 27 (H3K27me3), a repressive mark that silences differentiation genes, thereby maintaining the undifferentiated state of CSCs. Conversely, histone acetylation, mediated by histone acetyltransferases (HATs), generally promotes a more open chromatin structure, leading to increased transcriptional activity of genes involved in CSC proliferation and survival [9].

Non-coding RNAs: Non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play a significant role in post-transcriptional regulation of gene expression. They influence various aspects of CSC biology, including self-renewal, differentiation, and resistance to therapies.

MiRNAs can act as oncogenes or tumor suppressors in CSCs. For instance, miR-200c has been found to suppress EMT by targeting ZEB1, a transcription factor involved in EMT and stemness. On the other hand, lncRNAs such as HOTAIR promote CSC traits by interacting with PRC2 to modify chromatin and silence genes involved in differentiation. The complex regulatory networks mediated by ncRNAs make them potential targets for disrupting CSC maintenance [10].

Targeting Epigenetic Regulation in CSSC for Cancer Therapy

DNA methylation inhibitors: Drugs targeting DNA methylation, such as 5-azacytidine and decitabine, have shown promise in reversing aberrant methylation patterns in CSCs. By inhibiting DNA methyltransferases (DNMTs), these agents can reactivate silenced tumor suppressor genes and promote CSC differentiation, rendering them more susceptible to conventional therapies. Clinical trials have demonstrated the potential of DNMT inhibitors in treating hematological malignancies, and their efficacy in solid tumors is being explored.

Histone modifying enzyme inhibitors: Histone deacetylase inhibitors (HDACis) are a class of drugs that have been investigated for their ability to modulate histone acetylation and affect gene expression in CSCs. Vorinostat and romidepsin, two FDA-approved HDAC inhibitors, have been used in combination with chemotherapy to target CSCs in various cancer types. Additionally, inhibitors of histone methyltransferases (HMTs), such as EZH2 inhibitors, are being explored for their ability to target repressive histone marks and promote CSC differentiation.

Non-coding RNA modulation: Given the pivotal role of ncRNAs in regulating CSC function, strategies to modulate their activity are being developed. AntagomiRs, synthetic molecules designed to inhibit oncogenic miRNAs, are being investigated as therapeutic agents to suppress CSC traits. Additionally, approaches to target lncRNAs involved in CSC maintenance are being explored, although these are still in early stages of development.

Challenges and Future Directions

Despite the promising potential of targeting epigenetic regulation in CSCs, several challenges remain. One of the primary issues is the specificity of epigenetic therapies. Because epigenetic modifications are reversible and dynamic, off-target effects may arise, potentially affecting normal stem cells and leading to unwanted side effects. Moreover, the heterogeneity of CSCs within tumors complicates the design of targeted therapies, as different subpopulations of CSCs may exhibit distinct epigenetic landscapes.

Another challenge is the development of resistance to epigenetic drugs. Similar to other targeted therapies, CSCs may adapt to epigenetic inhibitors, necessitating combination therapies to achieve sustained therapeutic responses. Combination strategies involving epigenetic drugs with immunotherapies, chemotherapies, or targeted therapies are being actively investigated to improve outcomes.

Conclusion

Epigenetic regulation is fundamental to the biology of cancer stem cells, influencing their self-renewal, differentiation, and resistance to therapy. Targeting the epigenetic machinery offers a promising avenue for developing novel cancer treatments aimed at eliminating CSCs and preventing tumor relapse. Although significant challenges remain, ongoing research into epigenetic therapies and combination strategies holds the potential to revolutionize cancer treatment by addressing the root cause of tumor recurrence and drug resistance.

References

1. Brooks D. A, Nover B. A, Jagtap S, Anjum W, Yegingil H, et al. (2009) Modern Breast Cancer Detection: A Technological Review. Int J Biomed Imaging 2009: 902326.

Indexed at, Google Scholar, Crossref

2. Maddams J, Brewster D, Gavin A, Steward J, Elliott J, et al. (2009) Cancer Prevalence in the United Kingdom: Estimates for 2008. Br J Cancer 101: 541-547.

Indexed at, Google Scholar, Crossref

3. Zubair M, Wang S, Ali N (2021) Advanced Approaches to Breast Cancer Classification and Diagnosis. Front Pharmacol 11: 632079.

Indexed at, Google Scholar, Crossref

4. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of Resistance to Systemic Therapy in Patients with Breast Cancer. Adv Exp Med Biol 608: 1-22.

Indexed at, Google Scholar, Crossref

5. Moqadam SM, Grewal PK, Zahra Haeri , Ingledew PA, Kohli K, et al. (2018) Cancer Detection Based on Electrical Impedance Spectroscopy: A Clinical Study. J Electr Bioimpedance 9: 17-23.

 Indexed at, Google Scholar, Crossref

6. Li X, Ma F, Yang M, Zhang J, (2022) Nanomaterial Based Analytical Methods for Breast Cancer Biomarker Detection. Mater. Today Adv 14: 100219.

Indexed at, Crossref

7. Sung H , Ferlay J, Siegel R.L, Laversanne M, Soerjomataram I, et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clin 71: 209-249.

Indexed at, Google Scholar, Crossref

8. Chinen AB, Guan CM, Jennifer JR, Barnaby SN, Merkel TJ, et al. (2015) Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence. Chem Rev 115: 10530-10574.

Indexed at, Google Scholar, Crossref

9. Azzouz A, Hejji L, Kim K-H, Kukkar D, Souhail B, et al. (2022) Advances in Surface Plasmon Resonance-Based Biosensor Technologies for Cancer Biomarker Detection. Biosens Bioelectron 197: 113767

Indexed at, Google Scholar, Crossref

10. Ulucan-Karnak F, Akgöl S (2021) A New Nanomaterial Based Biosensor for MUC1 Biomarker Detection in Early Diagnosis, Tumor Progression and Treatment of Cancer. Nanomanufacturing 1: 14-38

Indexed at, Google Scholar, Crossref